Risk Factors for Mortality in Patients with Septic Acute Kidney Injury in Intensive Care Units in Beijing, China: A Multicenter Prospective Observational Study
Author(s) -
Xin Wang,
Li Jiang,
Ying Wen,
Meiping Wang,
Wei Li,
Zhiqiang Li,
Xiuming Xi
Publication year - 2014
Publication title -
biomed research international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 126
eISSN - 2314-6141
pISSN - 2314-6133
DOI - 10.1155/2014/172620
Subject(s) - medicine , acute kidney injury , observational study , mechanical ventilation , apache ii , intensive care medicine , prospective cohort study , renal replacement therapy , intensive care unit , septic shock , kidney disease , mortality rate , intensive care , risk factor , emergency medicine , sepsis
Objective . To discover risk factors for mortality of patients with septic AKI in ICU via a multicenter study. Background . Septic AKI is a serious threat to patients in ICU, but there are a few clinical studies focusing on this. Methods . This was a prospective, observational, and multicenter study conducted in 30 ICUs of 28 major hospitals in Beijing. 3,107 patients were admitted consecutively, among which 361 patients were with septic AKI. Patient clinical data were recorded daily for 10 days after admission. Kidney Disease: Improving Global Outcomes (KDIGO) criteria were used to define and stage AKI. Of the involved patients, 201 survived and 160 died. Results . The rate of septic AKI was 11.6%. Twenty-one risk factors were found, and six independent risk factors were identified: age, APACHE II score, duration of mechanical ventilation, duration of MAP <65 mmHg, time until RRT started, and progressive KIDGO stage. Admission KDIGO stages were not associated with mortality, while worst KDIGO stages were. Only progressive KIDGO stage was an independent risk factor. Conclusions . Six independent risk factors for mortality for septic AKI were identified. Progressive KIDGO stage is better than admission or the worst KIDGO for prediction of mortality. This trial is registered with ChiCTR-ONC-11001875.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom